China Isotope & Radiation and Qeeka Home are both set to start pre-marketing tomorrow for Hong Kong
IPOs of about US$200m each, according to people close to the deals.
China I&R makes diagnostic and therapeutic radiopharmaceutical products for medical and industrial
applications. CICC is the sole sponsor.
China National Nuclear Corp controls 53.98% of the company through direct and indirect holdings,
including a direct stake of 44.47%.
According to a regulatory filing, the company posted a net profit of Rmb476m (US$74m) in 2017, up 9.5%
year on year.
Qeeka Home, which operates an online interior design and construction platform in China, plans to
pre-market the float for around a week, say two of the people.
The company posted a loss of Rmb856m (US$136m) for 2017, versus a loss of Rmb410m for 2016. CLSA and
Goldman Sachs are joint sponsors.